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Abstract
Background: International guidelines support an early invasive management strategy (including early coronary
angiography and revascularisation) for non-ST-elevation acute coronary syndrome (NSTE-ACS) in patients with renal
impairment. However, evidence from outside the UK suggests that this approach is underutilised. We aimed to describe
practice within the NHS, and to determine whether the severity of renal dysfunction influenced the provision of
angiography and modified the association between early revascularisation and survival.
Methods: We performed a cohort study, using multivariable logistic regression and propensity score analyses, of data from
the Myocardial Ischaemia National Audit Project for patients presenting with NSTE-ACS to English or Welsh hospitals
between 2008 and 2010.
Findings: Of 35 881 patients diagnosed with NSTE-ACS, eGFR of ,60 ml/minute/1.73 m2 was present in 15 680 (43.7%).
There was a stepwise decline in the odds of undergoing inpatient angiography with worsening renal dysfunction.
Compared with an eGFR.90 ml/minute/1.73 m2, patients with an eGFR between 45–59 ml/minute/1.73 m2 were 33% less
likely to undergo angiography (adjusted OR 0.67, 95% CI 0.55–0.81); those with an eGFR,30/minute/1.73 m2 had a 64%
reduction in odds of undergoing angiography (adjusted OR 0.36, 95%CI 0.29–0.43). Of 16 646 patients who had inpatient
coronary angiography, 58.5% underwent inpatient revascularisation. After adjusting for co-variables, inpatient
revascularisation was associated with approximately a 30% reduction in death within 1 year compared with those
managed medically after coronary angiography (adjusted OR 0.66, 95%CI 0.57–0.77), with no evidence of modification by
renal function (p interaction = 0.744).
Interpretation: Early revascularisation may offer a similar survival benefit in patients with and without renal dysfunction, yet
renal impairment is an important determinant of the provision of coronary angiography following NSTE-ACS. A randomised
controlled trial is needed to evaluate the efficacy of an early invasive approach in patients with severe renal dysfunction to
ensure that all patients who may benefit are offered this treatment option.
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Introduction
Thirty to forty percent of patients presenting with NSTE-ACS
have renal impairment [1]. Compared with patients with
preserved renal function those with impairment have a 2–5 fold
greater risk of death after NSTE-ACS; those with most severe
renal impairment being at highest risk [2]. The projected annual
cost to the National Health Service (NHS) of additional
cardiovascular events occurring in patients with chronic kidney
disease (12 000 myocardial infarctions and 7 000 strokes per year)
is £174–178 million [3].
Generally an ‘early invasive’ approach after NSTE-ACS –
characterised by routine coronary angiography, followed where
possible by early percutaneous or surgical revascularisation – has
been demonstrated to improve patient survival [4]. Yet patients
with renal impairment were under-represented in the clinical trials
that showed this benefit [5]. Current European and American
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guidelines advise early angiography after NSTE-ACS irrespective of
renal function [6,7]. However, several reports from outside the
UK suggest that patients with renal dysfunction are significantly
less likely to undergo angiography or subsequent revascularisation
[1,8–10]. Reasons for this discrepancy, between guidelines and
practice, are likely to be complex. Remaining uncertainty as to
whether renal dysfunction negates the benefit associated with early
revascularisation may contribute.
We used data from the Myocardial Ischaemia National Audit
Project (MINAP) to describe and quantify use of an early invasive
approach after NSTE-ACS in those with normal and those with
impaired renal function in NHS clinical practice. We investigated
the association between inpatient coronary angiography and
death. Furthermore, for patients undergoing inpatient angiogra-
phy, we investigated whether renal dysfunction at the time of
presentation modified the association between revascularisation
and death within 1 year.
Methods
Study Population
Care of patients presenting with ACS to all acute NHS hospitals
in England and Wales are monitored through MINAP [11–13].
Briefly, each patient entry contains prospectively collected
information on aspects of diagnosis, investigation and manage-
ment. The project uses highly secure electronic systems of data
entry and transmission, and allows linkage with the NHS Central
Register for mortality tracking. Assurance of data quality involves
continual monitoring of key fields and an annual validation
exercise. MINAP is supported by the British Cardiovascular
Society under the auspices of the National Institute for Cardio-
vascular Outcomes Research (NICOR) and is commissioned and
funded by the Healthcare Quality Improvement Partnership.
Anonymised data from an adult population with a diagnosis of
NSTE-ACS admitted to hospital between 1st Jan 2008 and 31st
March 2010 were used. The diagnosis of NSTE-ACS was made
by the local clinician using their judgement of presenting
symptoms and requiring elevated blood troponin concentration,
with or without electrocardiographic changes consistent with
ischaemia. Patients with ST elevation were excluded from this
analysis.
Study Exposures
The first single serum creatinine (mmol/l) within 24 hours of
admission was used to estimate the glomerular filtration rate
(eGFR) in ml/minute/1.73 m2 using the equation developed by
the Chronic Kidney Disease Epidemiology Collaboration (CKD
EPI) [14]. All creatinine values were assumed not to have been
calibrated by isotope dilution mass spectrometry and therefore
were multiplied by a 0.95 standardisation factor. Renal function
was initially categorised as eGFR.90 ml/minute/1.73 m2, eGFR
60–90 ml/minute/1.73 m2, eGFR 45–59 ml/minute/1.73 m2,
eGFR 30–44 ml/minute/1.73 m2, eGFR 15–29 ml/minute/
1.73 m2 and ,15 ml/minute/1.73 m2 for the descriptive analysis
[15]. As relatively low numbers of patients with an eGFR 15–
29 ml/minute/1.73 m2 and ,15 ml/minute/1.73 m2 underwent
inpatient coronary angiography or inpatient revascularisation the
two eGFR categories were combined for subsequent analyses
(eGFR,30 ml/minute/1.73 m2].
Inpatient revascularisation was defined as inpatient percutane-
ous coronary intervention (PCI) or coronary artery bypass grafting
(CABG). Patients were categorised as medically managed follow-
ing inpatient coronary angiography if i) PCI or CABG was
planned after discharge, or ii) the patient refused such interven-
tions, or iii) the procedures were neither planned nor performed
during the index admission.
Study Outcomes
The primary study outcomes were performance of inpatient
coronary angiography – dichotomised as performed or not
performed – and all-cause death within one year of presentation.
Patients who died on the day of admission were excluded from
analyses.
Confounder Variables
Demographic factors included age (10 year categories), sex,
ethnicity, hospital of admission and self- reported smoking status.
The Index of Multiple Deprivation was included. This index
reflects information on the seven domains of income: employment;
health and disability; education, skills and training; barriers to
housing and services; living environment; and crime [16]. Co-
morbidities included a history of hypertension, previous angina,
previous myocardial infarction, hyperlipidaemia, peripheral vas-
cular disease, cerebrovascular disease, chronic obstructive airways
disease, congestive cardiac failure, diabetes mellitus, previous PCI
and previous CABG. Haemoglobin (g/dl) recorded within 24
hours of admission and peak troponin were also used.
We lacked direct measurements of left ventricular function.
Surrogates for reduced function included a history of congestive
cardiac failure or previous myocardial infarction. Systolic blood
pressure (SBP) and heart rate at the time of admission are
validated prognostic markers in ACS and thought to be
representative of the degree of acute left ventricular dysfunction
[17]. The first SBP (mmHg) recorded after admission to hospital
was used. If the patient presented with a treatable tachyarrhyth-
mia, the first stable SBP after treatment was used. The heart rate
(beats/minute) was recorded from the first ECG after admission to
hospital, whilst in a stable cardiac rhythm. The ECG appearances
at presentation were included (normal, left bundle branch block,
ST segment depression, T wave changes only, other abnormality).
Statistical Analyses
All statistical analyses were done using STATA version 11.2.
Confounder exposure associations were cross-tabulated both in
the full study population and in the subgroup of patients
undergoing inpatient coronary angiography. The frequency and
proportions of missing data within each variable were tabulated
and distributions of population characteristics for participants
included in the complete case analysis were compared with
individuals who were excluded due to incomplete data on the a
priori variables.
Univariable and then multivariable logistic regression models
adjusted for all study covariables were used to estimate the odds
ratio for the association between eGFR category and undergoing
inpatient coronary angiography. Robust standard errors were used
to account for clustering at hospital level.
Logistic regression models were also used to assess the
association between inpatient coronary angiography and all-cause
death. As it was expected that in some cases those that did not
undergo inpatient angiography would vary substantially in their
baseline characteristics compared with those that did, a propensity
score was estimated to help ensure adequate overlap between the
distributions of confounders in the two treatment groups [18]. The
analysis was repeated restricting to a sub group of the cohort with
improved balance in baseline co-variables. The propensity score
was the conditional probability that an individual had inpatient
coronary angiography and was obtained for each individual by
fitting a logistic regression model with outcome inpatient coronary
Coronary Angiography, Revascularisation and Renal Impairment
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angiography with all the pre-specified co-variables included. All of
the pre-specified co-variables were considered a priori confounders.
Diagnostic coronary angiography is a pre-requisite for being
considered for revascularisation. The analysis to evaluate whether
renal dysfunction modified patient survival after inpatient coro-
nary revascularisation compared with medical management was
therefore limited to individuals who underwent inpatient coronary
angiography. Again a propensity score was estimated to help
ensure adequate overlap between the distributions of confounders
in the two treatment groups. The propensity score was the
conditional probability that an individual had inpatient revascu-
larisation, and was obtained for each individual by fitting a logistic
regression model with outcome inpatient revascularisation with all
the pre-specified co-variables. After estimation of the conditional
propensity score one patient from the medically managed group
was excluded as they could not be matched due to a very low
propensity score. Improved balance in the distribution in the co-
variables between the two treatment groups was achieved
(Appendix S1). Multivariable logistic regression analysis was
subsequently carried out using robust standard errors with
outcome death or alive within one year. Evidence of effect
modification between eGFR category and inpatient revascularisa-
tion or medical management on the odds of death within one year
was tested (Wald test). Evidence of effect modification between
gender and inpatient revascularisation or medical management
was also tested [19]. The interaction terms were maintained in the
model at a threshold of p,0.01. Results are presented as
multivariable adjusted odds ratios with 95% confidence intervals.
Sensitivity Analyses
Logistic regression with the propensity score included as the
single co-variable was conducted. Robust standard errors and
bootstrapping methods (50 repetitions) were used.
To evaluate possible bias introduced by patients who died early
after admission to hospital the analyses were repeated using a
cohort limited to individuals who survived five days or more.
Secondary preventative medications including aspirin, clopido-
grel, ACE inhibitors, beta-blockers and statins have been shown to
influence outcome after NSTE-ACS [20–23]. Whether these
medications were prescribed at time of discharge was included in
the multivariable model evaluating the association between
inpatient revascularisation and death within one year.
Sensitivity analysis using datasets derived using multiple
imputation was also conducted [24].
Ethical Approval
Ethics committee (11/L0/0246), Kings College Hospital
Research and Development (KCH11-081), and MINAP Academ-
Table 1. Selected covariates stratified by eGFR category at time of presentation in 35 881 adults presenting with non-ST-elevation
acute coronary syndrome (all data is presented as numbers with column percentage unless otherwise stated).
eGFR (ml/minute/1.73 m2)
.90 60–90 45–59 30–44 15–29 ,15
N=6 482 N=13 719 N=6 990 N=5 452 N=2 665 N=573
Demographic
Male gender 4781(73.8) 9223(67.2) 4010(57.4) 2749(50.4) 1326(49.8) 336(58.6)
Age, median (IQR) 58(50–66) 72(63–80) 79(72–85) 83(77–88) 84(78–88) 80(73–86)
Past Medical History
Hypertension 2680(41.4) 7089(51.7) 4161(59.5) 3375(61.9) 1671(62.7) 387(67.5)
Stroke 333(5.1) 1276(9.3) 950(13.6) 883(16.2) 439(16.5) 107(18.7)
PVD 241(3.7) 591(4.3) 442 (6.3) 390(7.2) 235(8.8) 71(12.4)
Treated hyperlipidaemia 2243(34.6) 4805(35.0) 2449(35.0) 1866(34.2) 854(32.1) 177(30.9)
CCF 128(2.0) 723(5.3) 688(9.8) 917(16.8) 584(21.9) 106(18.5)
Previous MI 1382(21.3) 3964(28.9) 2662(38.1) 2394(43.9) 1318(49.5) 256(44.7)
Previous PCI 787(12.1) 1488(10.9) 727(10.4) 549(10.1) 227(8.5) 52(9.1)
Previous CABG 362(5.6) 1121(8.2) 695(9.9) 536(9.8) 256(9.6) 57(10.0)
Diabetes Mellitus 1150(17.7) 2727(19.9) 1748(25.0) 1735 (31.8) 965(36.2) 235(41.0)
Current smoker 2820(43.5) 2948(21.5) 950(13.6) 520(9.5) 237(8.9) 59(10.3)
Diagnostics
Haemoglobin (g/dl), median (IQR) 14.2(13.0–15.2) 13.8(12.4–15.0) 13.0(11.7–14.1) 12.0(10.9–13.5) 11.3(10.0–12.6) 10.6(9.5–12.0)
Peak Troponin, median(IQR) 0.7(0.2–3.1) 0.7(0.2–3.3) 0.8(0.2–3.9) 0.9(0.2–4.1) 1.2(0.3–5.3) 1.7(0.4–8.2)
Systolic blood pressure (mmHg), mean (sd) 143(26) 144(28) 142(29) 140(30) 135(31) 137(33)
Heart rate (beats/min), median (IQR) 77(66–90) 78(66–93) 82(69–99) 85(71–101) 85(71–100) 86 (71–100)
IP Coronary angiography 4720(72.8) 7445(54.3) 2613(37.4) 1366(25.1) 416(15.6) 86(15.0)
IP revascularisation 2992(46.2) 4422(32.2) 1370(19.6) 697(12.8) 205(7.7) 46(8.0)
IP PCI 2758(42.5) 3977(29.0) 1208(17.3) 609(11.2) 183(6.9) 44(7.7)
IP CABG 234(3.6) 445(3.2) 162(2.3) 88(1.6) 22(0.8) 2(0.3)
Abbreviations: IMD score = score of deprivation; PVD=peripheral vascular disease; CCF = congestive cardiac failure; MI =myocardial infarction; PCI = percutaneous
coronary intervention; CABG= coronary artery bypass graft; eGFR= estimated glomerular filtration rate; IP - inpatient; IQR = interquartile range; sd = standard deviation.
doi:10.1371/journal.pone.0099925.t001
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ic Group approvals were obtained prior to commencement of the
analysis.
Results
Renal Impairment at the Time of Presentation with NSTE-
ACS and Subsequent Inpatient Coronary Angiography
GFR could not be estimated for 18.2% (16 632/91 342) due to
missing data on creatinine, gender, age or ethnicity (Appendix S2).
Data was missing regarding coronary angiography in 4.5%,
management strategy (inpatient revascularisation or medical
management) in 18.3% and for mortality in ,1% of patients.
15.8% of individuals excluded from the complete case analysis due
to incomplete data died compared with 19.0% of those included
(Appendix S3). Complete data on all co-variables was available in
35 881 cases. Approximately 40% (n= 15 680/35 881) had an
eGFR,60 ml/minute/1.73 m2, and 9.0% (n= 3 238) an eGFR,
30 ml/minute/1.73 m2 (Table 1). The median age was 75 years,
and 22 425 (62.5%) were male. Individuals with impaired renal
function tended to be older, with a higher co-morbid profile, and
more likely to die within 1 year (Table 1, Figure 1).
Inpatient coronary angiography was performed in 16 646
(46.4%) of the cohort. Patients who had inpatient coronary
angiography were more likely to be male, younger and have fewer
co-morbid conditions than those who did not (Table 2). Death
within 1 year occurred in 30.6% patients who did not undergo
inpatient coronary angiography compared with 5.7% in those that
did. 72.8% of individuals with normal renal function (an eGFR.
90 ml/minute/1.73 m2) underwent inpatient coronary angiogra-
phy compared with 15.5% of those with an eGFR,30 ml/
minute/1.73 m2 (Table 1).
After adjusting for all other comorbidities and covariables, there
was a stepwise reduction in the odds of undergoing inpatient
coronary angiography with increasing severity of renal impair-
ment; a reduction of 33% in patients with eGFR 45–59 ml/
minute/1.73 m2 (adjusted OR 0.67, 95% CI 0.55–0.81), 42% in
those with an eGFR between 30–44 ml/minute/1.73 m2 (adjusted
OR 0.58, 95% CI 0.48–0.70), and 64% in those with eGFR,
30 ml/minute/1.73 m2 (adjusted OR 0.36, 95% CI 0.29–0.43)
compared with patients with an eGFR.90 ml/minute/1.73 m2
(Table 3).
Renal Impairment at the Time of Presentation with NSTE-
ACS and the Association between Inpatient Coronary
Angiography and Death within 1 Year
In patient coronary angiography was associated with a survival
benefit in each eGFR category (Table 4). In those with an eGFR
60–90 ml/minute/1.73 m2 inpatient coronary angiography was
associated with a reduction in the estimated odds of death of 70%
(adjusted OR 0.29, 95% CI 0.25–0.33) and by 54% in those with
an eGFR,30 ml/minute/1.73 m2 (adjusted OR 0.46, 95%CI
0.36–0.58). On restricting the analysis to a subgroup with
improved balance in the distribution of baseline characteristics
based on estimated propensity score (N= 16 617), the estimated
survival benefit observed did not change, except in those with an
eGFR,30 ml/minute/1.73 m2 in whom the estimated survival
benefit was more conservative (adjusted OR 0.59, 95% CI 0.37–
0.96) (data not shown).
Figure 1. Percentage of patients that died within 1 year after non-ST-elevation acute coronary syndrome. Percentage of patients that
died within 1 year after non-ST-elevation acute coronary syndrome stratified by category of estimated glomerular filtration rate at the time of
presentation and whether inpatient coronary angiography was performed. *Abbreviations eGFR= estimated glomerular filtration rate; *this analysis
included 35 881 patients presenting with NSTE-ACS.
doi:10.1371/journal.pone.0099925.g001
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Table 2. Selected covariates stratified by whether inpatient coronary angiography was performed or not, in 35 881 adults
presenting with non-ST-elevation acute coronary syndrome (all data is presented as numbers with column percentage unless
otherwise stated).
IP Coronary angiography not performed IP Coronary angiography performed
N=19 235 N=16 646
Demographic
Male gender 10 821 (56.3) 11 604 (69.7)
Age in years, median (IQR) 81 (72–87) 68 (56–76)
Past Medical History
Hypertension 10 631 (55.3) 8 732 (52.5)
Stroke 2 842 (14.8) 1 146 (6.9)
PVD 1 228 (6.4) 7 42 (4.5)
Treated hyperlipidaemia 5 717 (29.7) 6 677 (40.1)
CCF 2 466 (12.8) 680 (4.1)
Previous MI 7 586 (39.4) 4 309 (26.4)
Previous PCI 1 559 (8.3) 2 231 (13.4)
Previous CABG 1 736 (9.0) 1 291 (7.8)
Diabetes Mellitus 5 030 (26.2) 3 530 (21.2)
Current smoker 2 912 (15.1) 46 22 (27.8)
Diagnostics
Haemoglobin (g/dl), median (IQR) 12.6 (11.0–14.0) 14.0 (12.8–15.0)
Peak Troponin, median (IQR) 0.8 (0.2–3.7) 0.8 (0.2–3.6)
eGFR (ml/minute/1.73 m2)
.90 1 762 (9.2) 4 720 (28.4)
60–90 6 274 (32.6) 7 445 (44.7)
45–59 4 377 (22.8) 2 613 (15.7)
30–44 4 086 (21.2) 1 366 (8.2)
15–29 2 249 (11.7) 416 (2.5)
,15 487 (2.5) 86 (0.5)
Systolic blood pressure (mmHg), mean (sd) 140 (29) 145 (27)
Heart rate (beats/min), median (IQR) 84 (70–100) 76 (65–90)
Abbreviations: IP = inpatient; IMD score = score of deprivation; PVD=peripheral vascular disease; CCF = congestive cardiac failure; MI =myocardial infarction;
PCI = percutaneous coronary intervention; CABG= coronary artery bypass graft; eGFR= estimated glomerular filtration rate; IQR = interquartile range; sd = standard
deviation.
doi:10.1371/journal.pone.0099925.t002
Table 3. Results of the multivariable logistic regression analysis in 35 881 individuals with non-ST-elevation acute coronary
syndrome for the association between eGFR and inpatient coronary angiography.
eGFR
(ml/minute/1.73 m2)
Age & gender
adjusted OR
(95% CI)
P-value
(Wald)
Multivariable
Adjusted OR
(95% CI)*
P-value
(Wald)
.90 1 1
60–90 0.81 (0.71–0.93) 0.003 0.81 (0.70–0.94) 0.006
45–59 0.58 (0.48–0.70) ,0.001 0.67 (0.55–0.81) ,0.001
30–44 0.42 (0.35–0.51) ,0.001 0.58 (0.48–0.70) ,0.001
,30 0.21 (0.18–0.26) ,0.001 0.36 (0.29–0.43) ,0.001
*Multivariable model adjusted for age, ethnicity, gender, IMD score, systolic blood pressure, heart rate, haemoglobin, peak troponin, ECG diagnosis, history of angina,
hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status and hospital.
Abbreviations: OR = odds ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0099925.t003
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Renal Impairment at the Time of Presentation with NSTE-
ACS and the Association between Inpatient
Revascularisation and Death within 1 Year
Of 16 646 patients who had inpatient coronary angiography, 9
732 (58.5%) underwent inpatient revascularisation (Figure 2). On
the basis of the propensity score, there was good overlap in the
distribution of baseline characteristics between the group that
underwent inpatient revascularisation and those who underwent
angiography only (Appendix S1). Only 16% of patients with severe
renal dysfunction at presentation (eGFR,30 ml/min/1.73 m2)
underwent inpatient coronary angiography and could be consid-
ered for early revascularisation. However, of the 502 patients in
this renal category that did have diagnostic angiography, nearly
50% underwent subsequent inpatient revascularisation (Table 5).
The adjusted odds of undergoing inpatient revascularisation did
not vary depending on eGFR category (data not shown).
538 deaths (7.8%) occurred within a year in those patients
managed medically after inpatient coronary angiography com-
pared with 413 deaths (4.2%) amongst patients who had inpatient
revascularisation. After adjusting for co-variables, inpatient
revascularisation was associated with a reduction in the odds of
death within 1 year of approximately 30% (adjusted OR 0.66,
95%CI 0.57–0.77) (Table 6). When stratified by eGFR category
there was a trend that the relative survival benefit of inpatient
revascularisation may be less in those with an eGFR,30 ml/
minute/1.73 m2 (adjusted OR 0.80, 95% CI 0.52–1.24) compared
with the other eGFR categories (eGFR 60–90 ml/minute/
1.73 m2 adjusted OR 0.63, 95% CI 0.49–0.81). However the
confidence intervals between eGFR categories overlapped and
there was no statistical evidence of modification by severity of
renal dysfunction on the association between inpatient revascular-
isation and death (p-interaction= 0.744) (Table 6 and 7). There
was weak evidence of effect modification by gender on this
association with a trend to a lower adjusted odds of death in
women (p-interaction = 0.060).
Sensitivity Analysis
Results of the logistic regression model adjusted for the
propensity score as a single co-variable demonstrated a similar
reduction in the odds for death within 1 year associated with
inpatient revascularisation (adjusted OR 0.68, 95% CI 0.58–0.80,
Table 6).
Limiting the analysis to 5-day survivors did not alter the
associations observed (Appendix S4a, 4b and 4c).
We repeated the analysis excluding 116 patients who had
declined revascularisation. No change in the associations found in
our main analysis was observed (data not shown).
Inclusion of aspirin, clopidogrel, ACE inhibitors, beta-blockers
or statins prescribed at discharge in the model did not change the
adjusted odds for death associated with inpatient revascularisation
within 1 year (adjusted OR 0.68, 95% CI 0.57–0.80), with no
evidence of modification by severity of renal dysfunction (p-
interaction= 0.711).
After multiple imputation, the adjusted odds ratios were
marginally more conservative (Appendix S5a and 5b; data not
shown for the analysis of the association between inpatient
coronary angiography and death).
Discussion
In this study of over 35 000 individuals with NSTE-ACS in
England and Wales, admitted to NHS hospitals between 2008 and
2010, we have demonstrated that renal dysfunction is common
and that patients with renal impairment are much less likely to
undergo inpatient diagnostic coronary angiography than patients
with normal renal function. This association was maintained after
adjusting for differences in numerous baseline characteristics and
comorbidities and was observed across the range of renal
impairment, including those patients with moderate renal
dysfunction (eGFR 30–59 ml/minute/1.73 m2). Inpatient coro-
nary angiography was associated with an improved survival. In
those patients with moderate renal dysfunction that did undergo
inpatient angiography, nearly 50% of patients then underwent
Table 4. Results of the multivariable logistic regression analysis in 35 881 individuals with non-ST-elevation acute coronary
syndrome for the association between inpatient coronary angiography and all-cause death.
eGFR
(ml/minute/1?73 m2)
Inpatient
angiography status
Multivariable
Adjusted OR
(95% CI)*
P-value
(Wald)
.90 Inpatient angiography not performed 1
Inpatient angiography 0.21 (0.17–0.27) ,0.001
60–90 Inpatient angiography not performed 1
Inpatient angiography 0.29 (0.25–0.33) ,0.001
45–59 Inpatient angiography not performed 1
Inpatient angiography 0.37 (0.32–0.43) ,0.001
30–44 Inpatient angiography not performed 1
Inpatient angiography 0.41 (0.34–0.48) ,0.001
,30 Inpatient angiography not performed 1
Inpatient angiography 0.46 (0.36–0.58) ,0.001
*p-interaction (Wald test) between eGFR category and inpatient coronary angiography and mortality: ,0.001.
*Multivariable model adjusted for age, ethnicity, gender, IMD score, systolic blood pressure, heart rate, haemoglobin, peak troponin, ECG diagnosis, history of angina,
hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status and hospital.
Abbreviations: OR = odds ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0099925.t004
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revascularisation with a similar survival benefit as seen in patients
with preserved renal function.
The majority of patients (84%) with severe renal dysfunction
(eGFR,30 ml/min/1.73 m2) did not undergo inpatient diagnos-
tic angiography. Therefore it is unclear whether, amongst this
large group without inpatient diagnostic angiography, early
revascularisation in those with suitable coronary lesions would
have imparted a survival benefit.
Our finding that patients with renal dysfunction are less likely to
undergo early coronary angiography than patients with preserved
renal function is supported by several other analyses from different
health care systems [1,8–10,25]. We suspect that the reasons are
complex, reflecting both individual patient and clinician level
factors as well as organisational factors spanning community and
hospital level care. Patients with renal dysfunction are more likely
to present with atypical clinical features [25,26] and not
necessarily directly to cardiologists. Clinical uncertainty as to the
interpretation of troponin measurements in patients with renal
impairment can compound diagnostic difficulties [27]. Concerns
regarding the risk of acute kidney injury (AKI), in particular
related to contrast-induced AKI, or a presumed increased risk of
bleeding complications are also likely to influence management
decisions [6,28]. However, recent work suggests the risks of AKI
associated with coronary angiography after ACS are overstated
[9]. In addition, routine coronary angiography as part of renal
transplant work-up in patients with advanced renal impairment is
not associated with an accelerated decline in renal function [29].
As many patients with NSTE-ACS undergo angiography on a
semi-urgent basis there are opportunities for clinicians to ensure
adequate hydration and optimal angiographic practices that
reduce the risk of AKI. In a previous study from the GRACE
collaboration the most commonly reported reason for foregoing an
early-invasive management strategy in those with renal impair-
ment was insufficient risk (37.7%), while concerns over comor-
bidity (12.5%) and bleeding (7.2%) were minor in comparison
[30]. However, the median GRACE score of those patients
deemed ‘low risk’ was paradoxically high. Misrepresentation of
risk and resultant denial of early-invasive management may
contribute to worse outcomes in patients with renal dysfunction
Table 5. Selected covariates stratified by management strategy in 16 646 adults who underwent inpatient coronary angiography
presenting with non-ST-elevation acute coronary syndrome.
In patient Medical
Management
In Patient
Revascularisation
N=6 914 N=9 732
Demographic
Male gender 4 552 (65.8) 7 052 (72.5)
Age in years, median (IQR) 69 (60–77) 66 (57–75)
Past Medical History
Hypertension 3 784 (54.7) 4 948 (50.8)
Stroke 563 (8.1) 583 (6.0)
PVD 359 (5.2) 383 (3.9)
Treated hyperlipidaemia 2 709 (39.2) 3 968 (40.8)
CCF 369 (5.3) 311 (3.2)
Previous MI 2 050 (29.7) 2 340 (24.0)
Previous PCI 912 (13.2) 1 319 (13.6)
Previous CABG 618 (8.9) 673 (6.9)
Diabetes Mellitus 1 594 (23.1) 1 936 (19.9)
Current smoker 1 656 (24.0) 2 966 (30.5)
Diagnostics
Haemoglobin (g/dl), median (IQR) 13.8 (12.5–15.0) 14.0 (13.0–15.0)
Peak Troponin, median(IQR) 0.9 (0.2–4.0) 0.8 (0.2–3.3)
eGFR (ml/minute/1.73 m2)
.90 1 728 (25.0) 2 992 (30.7)
60–90 3 023 (43.7) 4 422 (45.4)
45–59 1 243 (18.0) 1 370 (14.1)
30–44 669 (9.7) 697 (7.2)
15–29 211 (3.1) 205 (2.1)
,15 40 (0.6) 46 (0.5)
Systolic blood pressure (mmHg), mean (sd) 144 (27) 145 (28)
Heart rate (beats/min), median (IQR) 79 (67–93) 76 (65–88)
Abbreviations: PVD=peripheral vascular disease; CCF = congestive cardiac failure; MI =myocardial infarction; PCI = percutaneous coronary intervention;
CABG= coronary artery bypass graft; eGFR= estimated glomerular filtration rate; IQR = interquartile range; sd = standard deviation.
All data is presented as numbers with column percentage unless otherwise stated. Where percentages do not equal 100% this is due to rounding.
doi:10.1371/journal.pone.0099925.t005
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Figure 2. Number of patients in the complete case analysis contributing to various stages of the analysis.
doi:10.1371/journal.pone.0099925.g002
Table 6. Results of the adjusted logistic regression analysis in 16 645 individuals with non-ST-elevation acute coronary syndrome
for the association between inpatient revascularisation and mortality compared with individuals who were medically managed
after inpatient coronary angiography.
Management
Strategy
Age & gender
adjusted
OR (95% CI)
P-value
(Wald)
Multivariable
Adjusted OR
(95% CI)*
P-value
(Wald)
Propensity
score adjusted
OR (95% CI)
P-value
(Wald)
Medical Mx 1 1 1
In patient Revascularisation 0.60(0.52–0.70) ,0.001 0.66(0.57–0.77) ,0.001 0.68(0.58–0.80) ,0.001
*p-interaction (Wald test) between eGFR category and inpatient revascularisation and mortality: 0.744.
Multivariable Model adjusted for age, ethnicity, gender, IMD score, eGFR, systolic blood pressure, heart rate, haemoglobin, peak troponin, ECG diagnosis, history of
angina, hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status and hospital.
Propensity Score estimated using age, ethnicity, gender, IMD score, eGFR, systolic blood pressure, heart rate, haemoglobin, peak troponin ECG diagnosis, history of
angina, hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status.
Abbreviations: Medical Mx =medical management; OR = odds ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0099925.t006
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[30], and in other high risk groups in whom the same treatment
paradox has been observed [31–33].
Earlier major clinical trials have compared a routine early
invasive strategy with a selective invasive strategy after NSTE-
ACS, rather than outcomes after revascularisation specifically
[4,34–36]. Patients with renal impairment have been under-
represented in these studies [5] and no direct RCT evidence
regarding an early invasive strategy, or specifically outcomes after
revascularisation, are available in patients with renal impairment.
A systematic review and meta-analysis of individual level data
from five RCTs that had recorded information on renal function
suggested that the benefits of an early invasive strategy are
preserved in patients with renal impairment, with a trend in
reduction of risk of death and non-fatal re-infarction at one year
(in patients with chronic kidney disease (CKD) stages 3–5 i.e. an
eGFR,60 ml/minute/1.73 m2, a pooled estimate risk ratio 0.76
(95% CI 0.49–1.17) was reported) [37]. Among the studies
included in that meta-analysis the mean age ranged from 59–66
years, 14–28% had diabetes and mortality rates in the ‘conserva-
tive’ arms were 2.5–10%. Patients with CKD accounted for 19.4%
(1 453/7 481) with the majority having an eGFR 30–60 ml/
minute/1.73 m2 (80%). Our real world ACS cohort was quite
different to those in the RCTs. In our study, the median age was
75 years, 40% had an eGFR at time of presentation of ,60 ml/
minute/1.73 m2 and at one year 30% of those who did not
undergo inpatient coronary angiography had died.
Our analysis of the outcomes associated with inpatient coronary
angiography will have included people in the comparison group
(those that did not have inpatient coronary angiography) that
would have been excluded from the randomised trials, and would
therefore not have been considered for revascularisation, thus
suggesting a possibly overoptimistic benefit of an early invasive
approach. Some of the benefit observed in our comparison of
those receiving and those not receiving inpatient angiography may
also reflect other management differences between the groups,
such as more aggressive antiplatelet or adjunctive medical
therapies in the group in our cohort who underwent inpatient
coronary angiography [1]. Thus, to further evaluate whether renal
function modified outcomes after inpatient revascularisation we
restricted the analysis to those in whom a clinical decision to
consider revascularisation had been taken following inpatient
coronary angiography.
Previous registry-based analyses have reported varied results.
Data from the SWEDEHEART registry suggested that early
revascularisation improved 1-year survival in patients with NSTE-
ACS and mild-to-moderate renal insufficiency [8]. However, the
observed benefit declined with lower renal function, and there was
a trend toward harm in those with an eGFR,15 ml/minute/
1.73 m2 or on dialysis (HR 1.61 95% CI 0.84–3.09). The wide
confidence interval reflects the low number of patients in this
eGFR category (n = 278, with 41 patients undergoing early
revascularisation) making it hard to draw firm conclusions. In
our study there was no statistical evidence of modification by
eGFR category on the survival benefit associated with inpatient
revascularisation, a finding supported by a study from the GRACE
collaboration [30].
None of our analyses suggest that inpatient angiography or
subsequent revascularisation was associated with harm in patients
with renal dysfunction, though the fear of this may be influencing
clinical judgement and decision making. Consistent with previous
studies, the main barrier to revascularisation appears to be the
decision to undertake inpatient coronary angiography [30]. The
few patients with eGFR,30 ml/min/1.73 m2 that do undergo
diagnostic angiography may represent a highly select subset of
patients with severe renal impairment in whom an early invasive
approach is likely to be of most benefit. However, the efficacy of a
routine early invasive approach in individuals presenting with this
severity of renal dysfunction currently remains essentially unde-
fined.
Table 7. Results of the adjusted logistic regression analysis in 16 645 individuals with non-ST-elevation acute coronary syndrome
for the association between inpatient revascularisation and mortality compared with individuals who were medically managed
after inpatient coronary angiography stratified by category of renal dysfunction.
eGFR
(ml/minute/1.73 m2)
Management
Strategy
Multivariable
Adjusted OR
(95% CI)*
P-value
(Wald)
.90 Medical Mx 1
In patient Revascularisation 0.55(0.36–0.85) 0.008
60–90 Medical Mx 1
In patient Revascularisation 0.63(0.49–0.81) ,0.001
45–60 Medical Mx 1
In patient Revascularisation 0.69(0.51–0.95) 0.020
30–45 Medical Mx 1
In patient Revascularisation 0.68(0.49–0.94) 0.021
,30 Medical Mx 1
In patient Revascularisation 0.80(0.52–1.24) 0.320
*p-interaction (Wald test) between eGFR category and inpatient revascularisation and mortality: 0.744.
Multivariable Model adjusted for age, ethnicity, gender, IMD score, eGFR, systolic blood pressure, heart rate, haemoglobin, peak troponin, ECG diagnosis, history of
angina, hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status and hospital.
Propensity Score estimated using age, ethnicity, gender, IMD score, eGFR, systolic blood pressure, heart rate, haemoglobin, peak troponin ECG diagnosis, history of
angina, hyperlipidaemia, hypertension, peripheral vascular disease, cerebrovascular disease, chronic obstructive airways disease, congestive cardiac failure, previous
percutaneous coronary intervention, previous coronary artery bypass graft, previous myocardial infarction, diabetes, current smoking status.
Abbreviations: Medical Mx =medical management; OR = odds ratio; CI = confidence interval; eGFR = estimated glomerular filtration rate.
doi:10.1371/journal.pone.0099925.t007
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Our cohort from a national ACS registry provides the most
comprehensive account of current clinical practice in England and
Wales in terms of the relationships between renal function, early
angiography and revascularisation and patient outcomes after
NSTE-ACS, and adds further contemporary data to the available
research in this field. We have taken account of a range of
confounders and have conducted multiple sensitivity analyses,
including using datasets derived from multiple imputation, the
results of which have supported the findings of our main analyses.
However, there are limitations. Most importantly, this is an
observational study and not a randomised controlled trial.
Confounding may be present although we aimed to minimise this
by incorporating a propensity score methodology and a wide
range of baseline characteristics. We did not have a direct measure
of true kidney function and used eGFR based on the CKD-EPI
formula. As only a single creatinine was available for each patient
we were unable to evaluate the components of chronic kidney
disease or acute kidney injury. Our conclusions therefore refer to
renal function at the time of presentation. However, given that
historical creatinine values may not always be available to
practising clinicians when they make decisions regarding angiog-
raphy or revascularisation we argue that the findings of this
analysis are relevant to clinical practice. Currently, identification
of patients on dialysis or those with a renal transplant is not
possible within the MINAP dataset. Very few individuals with an
eGFR,30 ml/minute/1.73 m2 contributed to the analysis fo-
cussed on inpatient revascularisation and survival as so few had an
inpatient coronary angiogram, so it is very likely that individuals
on dialysis were excluded. We did not have details of coronary
anatomy. After coronary angiography some patients will be
treated medically because no treatable culprit lesion is present and
others because revascularisation carries unacceptable risk or is
unlikely to be successful. Having this information would enable a
much more detailed description of the differences between patients
with various degrees of renal function, and a deeper understanding
of management strategies used and patient outcomes. We lacked
information on other important characteristics that stratify risk (in
patients who are not offered a routine invasive approach), for
example the results of stress tests and measurements of left
ventricular function. Nor did we have information on clinical
events in hospital, such as further myocardial infarction, which
may have influenced clinical decision making. While we were able
to categorise patients into those with and those without
angiography (and subsequent revascularisation) we lacked infor-
mation regarding delay from admission to intervention. To
evaluate the risk of potential survivor bias we undertook sensitivity
analyses restricted to those who survived more than five days, but
this is an important limitation. Other outcomes such as cardiac
specific mortality, in-hospital mortality and length of stay would be
valuable additional information. As mentioned above, our analysis
may also have lacked power to detect evidence of modification by
category of renal dysfunction on outcomes by management
strategy due to the relatively low numbers of individuals with
severe renal impairment contributing to that analysis.
Our analyses from MINAP provide further evidence that
patients with renal dysfunction are much less likely to undergo
inpatient coronary angiography than individuals with preserved
renal function which is not explained by associated comorbidity.
Inpatient coronary angiography was associated with improved
survival across all categories of renal dysfunction. After inpatient
angiography, relative outcomes following revascularisation were
not modified by severity of renal dysfunction. As in previous
studies however low patient numbers with severe renal dysfunction
limit the ability to draw firm conclusions.
There is a discrepancy between the care advised in clinical
guidelines regarding an early invasive strategy in patients with
renal dysfunction and NSTE-ACS, and care delivered in clinical
practice. Further research is required to understand why this
variation exists and determine whether there are missed oppor-
tunities for quality improvement. In patients with severe renal
impairment or those on dialysis a RCT is required to definitively
evaluate the efficacy and optimal timing of early angiography and
subsequent revascularisation after NSTE-ACS.
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